相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
The global burden of kidney disease and the sustainable development goals
Valerie A. Luyckx et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2018)
Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients
Dragana Lovre et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
Gianluigi Savarese et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity
Jana Grune et al.
HYPERTENSION (2018)
The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
Jonatan Barrera-Chimal et al.
KIDNEY INTERNATIONAL (2018)
Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure
O. Ola Vedin et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease Role of Oxidative Stress
Lionel Lattenist et al.
HYPERTENSION (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Diabetes with early kidney involvement may shorten life expectancy by 16 years
Chi Pang Wen et al.
KIDNEY INTERNATIONAL (2017)
Diabetic Kidney Disease Challenges, Progress, and Possibilities
Radica Z. Alicic et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
Jana Grune et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials
Jie V. Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
Frank Y. Ma et al.
PLOS ONE (2015)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
Louis L. Huang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Aldosterone antagonists for preventing the progression of chronic kidney disease
Davide Bolignano et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update Foreword
Michael V. Rocco et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure
Masayuki Yamaji et al.
AMERICAN HEART JOURNAL (2010)
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease
Scott D. Solomon et al.
CIRCULATION (2007)
Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes
JI Davies et al.
DIABETOLOGIA (2004)
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
CAJ Farquharson et al.
CIRCULATION (2000)
分享论文
